CHAPTER N0.

28

Challenges in Treating Multidrug-Resistant Infections

SANA JAVED[1*], RAHMA HAMAYUN[1], SANA SHAHZAD[1], MUHAMMAD SALEEM MALIK[2], ANEEQA AMBER[1], MARRIAM ABID[1]

[1]Department of Pharmacy, The University of Faisalabad, Faisalabad, Pakistan
[2] Shaqra General Hospital, Shaqra Al Riyadh, Saudi Arabia
[*]Corresponding Authors: sanajaved.PHARM@tuf.edu.pk

ABSTRACT: Antimicrobial resistance is a major threat to contemporary medicine. Multidrug-resistant infections reduce the efficacy of regular antimicrobial treatment, promote longer hospital stays, higher treatment expenses, and increased fatality. This chapter covers the epidemiology, molecular biology, and clinical presentation of MDR pathogens dependent on WHO, CDC, and global data, as of 2023, 2024, 2023, respectively. Additionally, experimental and emerging diagnostic approaches, as well as novel therapeutic solutions, including antimicrobial stewardship, bacteriophage treatment, and host-directed agents, are addressed, while international collaborative policy is recommended. A thorough knowledge of the various aspects of MDR infections is indispensable for healthcare providers, microbiologists, and policy-makers aiming to sustain the potency of current antimicrobials and foster new therapeutic strategies.

Keywords: Antimicrobial resistance, Multidrug resistance, antimicrobial stewardship, Infection control, Novel therapeutics

INTRODUCTION

Antimicrobial resistance has emerged as a major public health concern, with several multidrug-resistant (MDR) strains undermining the efficacy of current therapy. The emergence and spread of multidrug-resistant bacterial infections are the key challenges to global health in the 21st century. The WHO has warned that if no action is taken, antimicrobial resistance could lead to up to 10 million deaths per year by 2050 (O'Neill, 2016). MDR pathogens are defined as bacteria resistant to at least one agent in three or more classes of antimicrobials. These superbugs, which range from methicillin-resistant Staphylococcus aureus and ESBL-producing Enterobacteriaceae to carbapenemase-producing *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, present a serious clinical challenge. Antibiotics have transformed medicine since their introduction in the mid-20th century. Their misuse in both human and veterinary therapy, as well as the absence of appropriate infection control processes, has accelerated the rise of resistant strains (Magiorakos et al., 2012).

Multidrug resistance continues to accelerate globally, now undermining standard care for common invasive infections. Recent WHO surveillance data (Gandra et al., 2020) indicate that approximately one in six bacterial infections are resistant to first-line antibiotics, with the heaviest burden in the South-East Asia and the Eastern Mediterranean regions. In 2024, member states endorsed a UN political declaration committing to measurable antimicrobial resistance (AMR) targets by 2030 (WHO, 2024).

The complexity of MDR infections extends beyond microbial evolution to encompass clinical, diagnostic, pharmacological, and socioeconomic dimensions. This chapter explores these facts in detail, highlighting both challenges and emerging solutions in managing MDR infections. The "alarming trends" are strongest in low-income resource-poor countries, with the Eastern Mediterranean and South-East Asia hardest hit by untreated or inadequately treated high-level resistance. It was found that the most alarming findings relate to the rapid and worrisome increase of uncontrolled carbapenemases. The goal of this highly introductory chapter is to highlight the complexity of the disease by examining various important elements while considering time courses, the epidemiology of multidrug-resistant infections

EPIDEMIOLOGY OF MULTIDRUG-RESISTANT INFECTIONS

Global Burden

Recent surveillance by the WHO, Center for Disease Control and Prevention (CDC), and independent reviews underscores an alarming expansion of MDR bacterial infections. These infections are now responsible for approximately five million deaths every year worldwide. The burden is highest in low- and middle-income regions where limited diagnostic infrastructure, inconsistent stewardship practices, and widespread misuse of antibiotics compound the issue. One in six bacterial infections globally is now resistant to first-line antibiotics, with particularly severe rates in South-East Asia and the Eastern Mediterranean. The CDC reports a sharp rise in dangerous drug-resistant bacteria in the United States, including New Delhi metallo-β-lactamase–producing carbapenem-resistant Enterobacteriaceae (NDM-CRE).

Antimicrobial resistance is responsible for an estimated 4.95 million deaths annually with 1.27 million directly

How to Cite: Javed S, R Hamayun, S Shahzad, MS Malik, A Amber, M Abid, 2025. Challenges in treating multidrug-resistant infections. In: Advances in Pharmacology and Integrative Therapeutics (Aslam B, W Majeed, A Iftikhar, S Javed, I Abbas, Eds). FahumSci, Lahore, Pakistan, pp: 198-204. ISBN: 978-627-7745-13-4. https://doi.org/10.61748/APIT.2025/28

attributable to resistant bacterial infections (Murray et al., 2022). Low and middle-income countries bear the greatest burden due to limited diagnostic capacity, lack of stewardship, and unrestricted antibiotic sales (WHO, 2023). Updated WHO analyses reaffirm persistent regional disparities where limited infection prevention capacity fuels cycles of resistance (Hinson et al., 2024).

In Europe, approximately 33,000 people die annually due to resistant infections, most linked to healthcare settings (ECDC, 2023). In the United States, antimicrobial-resistant pathogens cause more than 2.8 million infections and 35,000 deaths per year (CDC, 2023). The 2024 AMR Preparedness Index report identified progress in policy development but slow advances in financing and infrastructure, especially in environmental and veterinary health integration (WHO, 2024).

Major MDR Pathogens

The WHO classifies "priority pathogens" according to public health urgency:

Critical priority: carbapenem-resistant *Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae (e.g., Klebsiella pneumoniae)*

High priority: MRSA, *Helicobacter pylori*, and fluoroquinolone-resistant *Salmonella species.*

Medium priority: penicillin-non-susceptible *S. pneumoniae* and ampicillin-resistant *Haemophilus influenzae* (WHO, 2023).

Carbapenem-resistant *K. pneumoniae* is endemic in South Asia and the Mediterranean, while MRSA remains prevalent in North America and Europe (ECDC, 2023; CDC, 2023).

MECHANISMS OF RESISTANCE

Resistance to antimicrobial agents develops chiefly in two ways: random changes in bacterial chromosomes and the uptake of foreign resistance genes from other microorganisms. These processes allow bacteria that carry advantageous genetic traits to persist and multiply when exposed to drugs. In many major pathogens, clinically important resistance traits are often obtained from external genetic elements such as plasmids, integrons, and transposons, which move between bacteria and deliver genes that inactivate drugs, alter drug targets, or reduce drug entry. Once acquired, these genes can spread rapidly through bacterial populations, especially in environments with frequent or inappropriate antimicrobial use.

Several distinct biological processes drive this gene movement, including direct cell-to-cell transfer, viral transfer by bacteriophages, uptake of free deoxyribonucleic acid from the environment, and transport in membrane vesicles. Together, these mechanisms accelerate the circulation of resistance genes across different species and settings, strengthening bacterial survival whenever antimicrobial agents are present (Wachino et al., 2025)

Bacteria have developed a myriad of enzymes that can inactivate a variety of antibiotic classes, such as aminoglycosides, macrolides, and chloramphenicol, in addition to the classical β-lactamases. Despite structural and genetic evidence, the discovery of novel β-lactamase variants with altered substrate specificity and increased hydrolytic rates highlights the differentiation among these enzyme classes. Plasmids and transposons have helped distribute resistance determinants throughout various identified resistance factors (Tao et al., 2022). Enzyme evolution puts newly developed drugs at risk of inefficacy. Outer membrane permeability reduction is a common response to antibiotic exposure by bacteria that rely heavily on the efflux pump AcrAB-TolC (a tripartite multidrug efflux pump in Gram-negative bacteria). β-lactamases hydrolyze β-lactam antibiotics, including penicillins, cephalosporins and carbapenems. Extended-spectrum β-lactamases and carbapenemases such as *Klebsiella pneumoniae carbapenemase, New Delhi metallo-beta-lactamase, and oxacillinase-48* are highly resistant to all β-lactams. This resistance phenotype displays a crucial role for efflux pump systems like AcrAB-TolC in structural studies (Smith et al., 2024).

Target Site Alterations

Target site mutations are frequently linked with a fitness cost to bacteria; however, compensatory changes may reduce this disadvantage, allowing resistant strains to survive and spread. In addition to well-known mutations in penicillin-binding proteins and DNA gyrase, mutations in novel targets such as ribosomal RNA and endotoxin lipid A in Gram-negative bacteria have recently been reported in ESKAPE pathogens *(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species)* a group of pathogens notable for multidrug resistance, including emerging resistance to polymyxin antibiotics providing resistance to polymyxins. These genetic alterations allow bacteria to elude antimicrobial action by subtle changes in the binding of the drug, resulting in an ongoing problem for drug design and resistance mutation monitoring. Mutations in antibiotic-binding sites on MRSA PBPs and DNA gyrase and topoisomerase IV result in fluoroquinolone resistance, among other things (Konkova et al., 2025).

Efflux Pumps and Permeability Barriers

Efflux pumps such as AcrAB-TolC are increasingly recognized not only for lowering intracellular antibiotic concentrations but also for promoting biofilm formation and modulating bacterial virulence. Efflux systems that overexpress AcrAB-TolC are responsible for many resistance genes that are transferred horizontally across bacterial species. Some efflux systems have a broad resistance spectrum. Additionally, changes in outer membrane porins, notably in Gram-negative bacteria, decrease drug distribution. Recent investigations of efflux pump expression as well as porin copy number emphasize the interrelatedness of efflux and permeability adjustments in isolates. Efflux systems such as AcrAB-TolC remove antibiotics from the bacterial cell while porins reduce drug entry (Smith et al., 2024).

Biofilm Formation

Bacteria in biofilms create a sheltered microenvironment in which they shift their gene expression profiles to upregulate stress response and efflux pump genes. The extracellular matrix around biofilm displays a physical barrier that hinders antibiotic penetration and a small sub-population of resistant persister cells. Recent advances have discovered that biofilms act as nuclear stabilizers of plasmids containing the genes conferring resistance against various environmental conditions. Modern medicine needs antibiotic-affected biofilm disruption therapies in combination with conventional antimicrobials to address persistent and indwelling infections. Biofilms establish up to a 1,000-fold increase in antibiotic resistance. Recent medical research reveals that biofilm-generated resistance subsists thanks to the slower rate of metabolism and accelerated efflux.

Horizontal Gene Transfer

Horizontal gene transfer (HGT) occurs through several mechanisms, including conjugation via plasmids, transduction by bacteriophages, and transformation with free DNA. Hospital effluents, wastewater, and agricultural environments are hotspots for HGT where high antibiotic selective pressures enhance the survival of resistant bacteria and facilitate gene spread. Outer membrane vesicles (OMVs) have recently been implicated as additional vehicles for the transfer of antimicrobial resistance genes, suggesting a more complex ecological network promoting resistance dissemination. Strategies to mitigate HGT require integrated environmental, agricultural, and clinical interventions within a One Health framework. Resistance genes spread via plasmids, transposons, and integrons, particularly in hospital effluents and agriculture (Murray et al., 2022).

Clinical Challenges in Treating MDR Infections

Diagnostic limitations

Traditional microbiological methods require several days, while expensive and innovative solutions delay patient-specific therapy to cope with the most severe cases. Other particularly advanced alternatives, such as nanopore sequencing, represent an imperative breakthrough that still lacks worldwide implementation. Additionally, another limitation of culture methods is that identification can require up to three days, positively delaying optimal therapy. Although these limitations can be ameliorated or eradicated through new molecular tools like PCR, MALDI-TOF, and nanopore sequencing, they are still relatively costly (Han et al., 2024).

Therapeutic limitations

Few antibiotics retain reliable effectiveness, such as polymyxins and tigecycline, which are generally last-resort agents with toxicities. Ceftazidime–avibactam, however, its use improves prognosis for CRE, although the emergence of resistance and MBL producers persists. Preformatted combinations like CAZ-AVI plus aztreonam may treat metallo-β-lactamase producers (Gupta et al., 2024). Meta-analyses between 2023 and 2024 indicate CAZ-AVI outcomerally versus polymyxins in CRE; this is the major challenge for MBL producers and may necessitate combinations such as CAZ-AVI + aztreonam. Biofilm-related infections, like prosthetic joint or lung infections, exhibit high tolerance and need prolonged or combination therapy.

Antibiotic dosing in critical illness

Critical illness profoundly alters antibiotic pharmacokinetics and pharmacodynamics by changing drug absorption, protein binding, volume of distribution, and clearance, which often leads to subtherapeutic or toxic concentrations when standard dosing regimens are used. Expanded extracellular fluid, capillary leak, hypoalbuminaemia, augmented renal clearance, or conversely renal and hepatic failure can all modify peak levels and half-life, making dose prediction difficult in intensive care unit patients.

Critically ill patients, therefore, often require individualized and sometimes prolonged or continuous infusion dosing strategies, guided by pharmacokinetic–pharmacodynamic principles and therapeutic drug monitoring, to maintain exposures above the minimum inhibitory concentration of the infecting pathogen. These challenges are compounded by organ dysfunction and by biofilm-associated infections, where bacteria in biofilms may show 10–1,000-fold higher tolerance to antibiotics due to altered metabolism, limited drug penetration, and biofilm-specific defense mechanisms (Chant et al., 2013).

Hospital transmission

Transmission of multidrug-resistant (MDR) organisms occurs mainly via healthcare workers' contaminated hands, along with medical equipment and hospital surfaces. Ineffective infection prevention and control (IPC) efforts worsen this issue by neglecting essential practices like hand washing, equipment decontamination, and surface sanitization, which hasten hospital-acquired outbreaks globally (WHO, 2024).

Weak IPC protocols enable MDR bacteria to linger on frequently touched items such as bed frames, computer terminals, and medical tools, where they remain viable for extended periods and facilitate patient-to-patient transfer. Around the world, healthcare staff adhere to hand hygiene only 40-60% of the time, a gap that directly fuels higher MDR rates in critical care areas. Improperly maintained devices like breathing machines and urinary catheters serve as key vectors when cleaning falls short of standards (Tao et al, 2022).

According to the World Health Organization, strong IPC initiatives—with monitoring, staff education, and regular checks—can cut MDR spread by as much as 50% in medical centers (WHO, 2024). In under-resourced areas, the absence of specialized IPC units results in erratic procedures and the swift proliferation of dangerous ESKAPE microbes. Biofilms clinging to surfaces and gear resist routine disinfectants, prolonging contamination risks. Deploying comprehensive IPC tactics, including hand sanitizers, isolation measures, and thorough environmental wipes, remains vital for containing MDR transmission in healthcare environments (Tao et al, 2022).

Socioeconomic barriers

Cost differences and restricted access to new antibiotics are more problematic. MDR spreads primarily through touch, devices, and surfaces, but inadequate infection control leads to spread across healthcare networks. On average, Treatment of multidrug-resistant (MDR) infections typically costs two to three times more than standard antimicrobial regimens due to prolonged hospital stays, specialized diagnostics, and reliance on expensive last-resort drugs (WHO, 2023; Murray et al., 2022).

CURRENT TREATMENT STRATEGIES

Combination Therapy

Continued research in the field suggests that the most important area of focus is the use of tailored combinations based on the patient's resistance profile variant. Precision medicine allows the determined use of powerful combinations for all types of infections and is underlined by rapid molecular diagnostics. New combination solutions appear to be leads in targeting novel resistance mechanisms involving efflux pump function and biofilm-producing bacterial phenotypes. In vitro synergy and animal models indicate that combinations such as colistin with carbapenems can be potentiated by adjunctive agents that disrupt the biofilm matrix. In summary, adjunctive therapies like rifampicin have shown unexpectedly strong efficacy against severe biofilm-associated infections on prosthetic devices. However, their pharmacodynamics and potential drug-drug interactions remain intricate, requiring careful clinical oversight. The optimal path for combination therapy involves probabilistic application, dependent on susceptibility data and machine learning to design polymyxin regimens.

The combinations of β-lactam and β-lactamase inhibitors are a major innovation to combat β-lactamase-mediated resistance in Gram-negative bacteria. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam, among others, represent novel agents that broaden the activity of beta-lactams. These drugs inhibit serine beta-lactamases and some metallo-beta-lactamases, thereby restoring antimicrobial efficacy against nearly all beta-lactamase-producing Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa strains. Superior results in complicated UTIs, pneumonia, and bacteremia from carbapenem-resistant Enterobacterales compared to colistin and tigecycline have been documented in randomized clinical trials. Stewardship applications have been crucial to safeguarding the efficacy and role of these combinations. Available evidence supports first-line therapy for many MDR infections, given the enhanced safety and decreased nephrotoxicity of new BL/ BLI combinations compared to colistin (Aslan and Akova, 2022).

β-Lactam/β-Lactamase Inhibitor Combinations

Novel BL/ BLI mixtures have been approved and are available, each targeting particular resistance mechanisms and expanding the options offered. However, it is critical to remember that resistance mutations in β-lactamase enzymes arise and are transmitted quickly. Consequently, monitoring and rational use of molecular diagnostics will be essential for new BL/ BLI production, which may see an increasing number of inhibitors aimed at the next generation (Smith et al., 2024). These novel combinations with enhanced activity include ceftazidime-avibactam, meropenem- vaborbactam, and imipenem-relebactam as well. Emerging evidence supports their use as first-line therapies for many MDR infections, given their improved safety profiles and reduced nephrotoxicity compared to agents like colistin. New BL/BLI combinations continue to enter clinical use, targeting specific resistance mechanisms and expanding treatment options (Kaye et al., 2023; Murray et al., 2022). Nevertheless, the rapid emergence of resistance mutations in β-lactamase enzymes underscores the need for ongoing surveillance and rational use guided by molecular diagnostics. Future BL/BLI development may also incorporate inhibitors targeting next-generation β-lactamases and combination molecules with dual mechanisms. Novel combinations like ceftazidime–avibactam, meropenem–vaborbactam, and imipenem–relebactam provide improved activity (Gupta et al., 2024).

Novel and Repurposed Agents

Cefiderocol, a siderophore cephalosporin, exemplifies recent advances in novel agents designed against MDR Gram-negative pathogens. Its unique mechanism exploits bacterial iron transport systems to achieve enhanced penetration, making it highly effective against carbapenem-resistant *Acinetobacter, Pseudomonas, and Enterobacteriaceae*. Clinical trials and real-world data confirm robust activity, favorable safety, and efficacy in critically ill patients with hospital-acquired pneumonia and complicated urinary tract infections, including cases refractory to conventional antibiotics (McLeod et al., 2024).

Drug integration into therapeutic regimens depends on features such as spectrum, pharmacokinetics, and safety profiles, proving vital for delaying resistance emergence. Cefiderocol demonstrates strong potency against carbapenem-resistant Gram-negative bacteria (El Ghali et al., 2024). These advancements address pressing needs in multidrug scenarios by targeting resistant ESBL producers, biofilm-embedded pathogens, and carbapenemase carriers in intensive care. Early adoption of cefepime–enmetazobactam has reduced mortality in high-risk cases, while cefiderocol tackles difficult Acinetobacter and Pseudomonas strains often refractory to other agents. Combining these with susceptibility-driven diagnostics optimizes outcomes and curbs resistance spread in nosocomial settings. Overall, such novel tools extend beta-lactam utility against evolving threats like ESKAPE pathogens.

As a result, the above-described integration of these drugs into drug species is reliant on drug features and has proven to be critical in postponing drug outcomes (Keam et al., 2024).

EMERGING ALTERNATIVE THERAPIES

Bacteriophage Therapy

Bacteriophage therapy leverages the geostrategy of bacterial viruses, which precisely target and control multidrug-resistant pathogens through highly selective mechanisms. Unlike traditional antibiotics, which broadly affect host microbiomes and require detailed susceptibility profiling, phages offer specificity that minimizes collateral damage and ecological disruption. The safety and efficacy of phage therapy have already been seen in multiple sources, including ongoing clinical trials and case series, where response rates of 70-80% for otherwise untreatable infections have been recorded. Phage induces bacterial lysis through direct infection, penetrates biofilm, and sometimes desensitizes bacteria to antibiotics either due to genetic exchange or by overcoming resistance mechanisms such as efflux pumps. Engineered bacteriophages can deliver resistance-breaking enzymes or genetic payloads directly to target bacteria. However, key hurdles persist, including the need for swift, accurate diagnostics to pair specific phages with pathogens, plus issues around regulatory approval, production standardization, and unwanted immune responses in hosts (Wang et al., 2025).

However, in a post-antibiotic period, phage therapy is a vital adjunct or alternative, offering considerable advantage in terms of integrating it into One Health and ICU protocols. Bacteriophage therapy offers pathogen-specific lysis with normal flora preservation. Compassionate-use reports attest to the successful treatment of *Acinetobacter baumannii* and *Pseudomonas species* infections. Inhaled and intravenous treatments are now being tested in new trials (Schooley et al., 2017). New trials further validate the use of inhaled and intravenous phage treatments (Wang and Yu, 2025).

Antimicrobial Peptides (AMPs)

Antimicrobial peptides (AMPs) are short, naturally occurring or synthetic proteins that form part of the innate immune response across diverse life forms. Their primary mode of action is to disrupt bacterial cell membranes, causing lysis and death of the microbe. This "membrane-acting" mechanism makes AMPs inherently less susceptible to resistance development compared to drugs targeting specific bacterial enzymes or pathways. In addition to direct bactericidal activity, AMPs modulate host immunity—suppressing harmful inflammation and promoting tissue repair, offering an advantage in treating infections that also trigger severe immune responses (Li et al., 2023)

Recent breakthroughs in synthetic biology and peptide engineering have created novel AMPs of this generation, with increased activity, stability, and pharmacokinetics. Several AMPs may selectively bind MDR pathogens or their biofilms, while others synergize effectively with conventional antibiotics. A variety of preclinical research has revealed that AMPs target a wide range of bacteria, including those resistant to ultimate defense technology, and limit the likelihood of selecting resistance mutants when used together. However, important problems remain, namely, optimizing the AMP delivery method, which considers a possible in vivo degradation by neighboring proteases, and the biggest one, the step from laboratory evidence to human treatment (Li et al.,2023).

CRISPR-Cas Systems

CRISPR-Cas systems represent an advanced therapeutic approach for bacterial infections, delivering the selective precision of antibacterial targeting akin to antiviral mechanisms. The method relies on RNA guides that direct Cas proteins to cleave bacterial DNA, bypassing traditional resistance pathways by directly killing pathogens or inserting mutations that disrupt antibiotic resistance, sparing beneficial microbes due to its high specificity.

Researchers worldwide validate CRISPR delivery mechanisms through genetic tools. For instance, sulbactam–durlobactam—a beta-lactam/beta-lactamase inhibitor pair approved by the FDA in 2023—targets carbapenem-resistant *Acinetobacter baumannii* (CRAB) specifically. When combined with carbapenems, it serves as the recommended first-line treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by CRAB (Chant et al., 2013).

Recent reviews and FDA evaluations confirm substantial improvements in survival and clinical cure rates among recipients. This underscores a new paradigm in antimicrobial chemotherapy, merging molecular precision (like CRISPR) with stewardship to enhance efficacy and postpone resistance. CRISPR antimicrobials excel at excising resistance genes for targeted control, evolving beyond early gene-editing associations to offer precise elimination of threats (Chant et al., 2013).

Sulbactam–Durlobactam

Sulbactam–durlobactam is the first licensed combination that offers therapeutic options specifically against infections by carbapenem-resistant Acinetobacter baumannii. Sulbactam is a synthetic beta-lactam antibiotic with inherent activity against *Acinetobacter species*, in addition to multiple other antibiotic activity modifiers. The former, durlobactam, is a recent inhibitor of a wide variety of beta-lactamases, the most popular type of enzyme that gives rise to resistance to all beta-lactam antibiotics. By marketing beta-lactamase production, durlobactam renders sulbactam useful even in otherwise pan-resistant strains of Acinetobacter. Various large randomised controlled studies and observational studies after the release of the medication have confirmed significantly improved clinical success and survival over the use of sulbactam–durlobactam, particularly in environments where multidrug-resistant pathogens persist in the background (Dellit, T. H., 2007).

In addition, sulbactam–durlobactam was used in combination with other antibiotic categories for its additive antibacterial effect, echoing a broader trend toward synergistic therapy for resistant gram-negative pathogens. This β-lactam/β-lactamase inhibitor combination was approved in 2023 for CRAB infections (Kaye et al., 2023; McLeod et al., 2024).

Nanotechnology and Host-Directed Therapies

Nanotechnology has revolutionized antimicrobial delivery and infection control by providing new tools to work with biofilm-associated and multiple-drug infections. Nanoparticles, most commonly made from silver, chitosan, lipids, or polymers, are designed to help antibiotics penetrate bacterial communities, including those shielded by biofilms. Some nanoparticles are making themselves known on the battlefield while others are equipped with antibiotics, AMPs, or even CRISPR-Cas systems targeting constructs to target pathogens. This direct approach allows for a significant reduction of antibiotic doses while minimizing side effects and overcoming mainstay resistance mechanisms such as efflux pumps and encapsulation (Liu et al., 2024).

Concurrently, host-directed therapies are being developed to improve the human immune system in defending its territory. 'Hosts' can receive cytokine response-modulating drugs to ensure a balanced reaction, boost the phagocyte function, or install adult upgrades to the mucosal barriers. By offering a viable alternative to the development of novel antimicrobial agents, this therapeutic strategy modulates host defense mechanisms instead of directly targeting pathogens, thereby reducing the selective pressure that drives antibiotic resistance in highly virulent strains. Therefore, it can be concluded that nanotechnology and host-directed therapies represent a new era in treating resistant infections and open up opportunities to destroy attackers while letting the host survive the onslaught. Nanoparticles (e.g., silver, chitosan) enhance drug delivery and biofilm disruption (Liu et al., 2024).

DIAGNOSTICS AND PRECISION THERAPY

Advances in point-of-care genomics, particularly rapid adaptive nanopore sequencing, enable real-time therapeutic optimization and support earlier initiation of antimicrobial stewardship measures. Recent studies have shown that adaptive nanopore sequencing can deliver clinically actionable antimicrobial resistance profiles from blood cultures within hours (Han et al., 2024; Liu et al., 2024). These innovations markedly shorten the time required for antimicrobial de-escalation. Furthermore, implementation frameworks have demonstrated that the adoption of these technologies reduces diagnostic turnaround times and strengthens infection prevention and control (IPC) outcomes (Han et al., 2024).

INFECTION PREVENTION AND CONTROL (IPC)

IPC is the backbone of MDR containment, incorporating hand hygiene, environmental cleaning, patient isolation, and active surveillance. However, according to a recent overview, fewer than 40% of nations can demonstrate full IPC program implementation. Effective programs require an integrated leadership and surveillance culture. Hospital-based stewardship programs use IPC in conjunction with antibiotic prescribing to minimize resistance emergence, prevent hospital outbreaks, and have been catalyzed via pandemic-associated funding and cooperation. IPC surveys show that only approximately 40% of nations have full IPC program implementation internationally. Integration with stewardship is important for hospital outbreaks. Source-control interventions with proven performance include audit and feedback, fast de-escalation, and preauthorization. By mid-decade, the updated WHO and UN policy initiatives endorse a wider One Health methodology with human, animal, and environmental health cooperation. By 2030, the goal is to reduce AMR-associated morbidity and mortality. Ongoing dependence on regulatory oversight, laboratory capacity, and access will be reduced as the WHO brief highlights that <40% of countries report nationwide IPC each year.

ANTIMICROBIAL STEWARDSHIP (AMS)

Antimicrobial stewardship (AMS) programs are structured to ensure the appropriate selection, dosage, route of administration, and duration of antimicrobial therapy, thereby optimizing therapeutic outcomes while minimizing the emergence of resistance (WHO, 2024; CDC, 2023). The CDC's core elements—leadership commitment, accountability, drug expertise, tracking, reporting, and education—serve as a globally recognized framework for AMS implementation across healthcare systems (WHO, 2024). These elements collectively emphasize the integration of multidisciplinary teams involving clinicians, pharmacists, microbiologists, and infection prevention specialists to coordinate rational antibiotic use and promote sustainable antimicrobial practices (Dellit et al., 2023).

Evidence indicates that AMS interventions such as prospective audit-and-feedback and pre-authorization review significantly reduce inappropriate antimicrobial prescribing and improve adherence to guidelines (Klein et al., 2022; Rawson et al., 2023). Studies in high-intensity clinical environments, including emergency departments, demonstrate that AMS programs maintain efficacy under pressure, reducing unnecessary antibiotic exposure without compromising patient safety (Tseng et al., 2024). The integration of rapid molecular diagnostics and real-time data analytics into AMS activities further enhances decision-making by enabling early identification of pathogens and resistance determinants (Han et al., 2024; Liu et al., 2024).

Global coordination remains fundamental to addressing antimicrobial resistance (AMR), as transnational collaboration supports data sharing, harmonization of stewardship guidelines, and surveillance of resistance trends (WHO, 2024). Strengthening AMS through international partnerships, continuous professional education, and investment in advanced diagnostic technologies is critical to sustaining the effectiveness of current antimicrobials and safeguarding public health for the future (Ventola, 2024; WHO, 2025).

FUTURE SOLUTIONS

Future approaches to combating antimicrobial resistance (AMR) are increasingly shaped by artificial intelligence (AI)–driven drug discovery, vaccine development, and microbiome-based therapeutics. AI and machine learning technologies can identify novel antibacterial scaffolds, optimize peptide-based agents, and predict drug-target interactions with unprecedented precision. CRISPR-based editing systems further support resistance control by selectively disrupting resistance genes, while synthetic biology enables the rapid design and optimization of antimicrobial compounds for clinical use (Wan et al., 2024).

A unified One Health framework—integrating human, animal, and environmental health—is essential for reducing resistance transmission across ecosystems. AI-enabled discovery platforms now produce genuinely novel antibacterial classes by mining extensive peptide libraries and reviving molecular structures through “molecular de-extinction” techniques. These scientific advances are poised to form the foundation of cross-sectoral interventions such as new vaccine design, improved water and sanitation systems, and enhanced global stewardship training—key to mitigating multidrug resistance (MDR) progression beyond 2030.

CONCLUSION

The next generation of antimicrobials will increasingly depend on explainable deep learning algorithms, high-throughput molecular screening, and AI-guided discovery to overcome evolving resistance mechanisms. When integrated within the One Health framework, these technologies offer a pathway toward sustainable antimicrobial development and global resilience against multidrug-resistant pathogens. Continued collaboration across health sectors, combined with investment in innovation, stewardship, and preventive infrastructure, will be essential to achieving the global goal of reducing AMR burden beyond 2030.

REFERENCES

Aslan AT and M Akova, 2022. The role of colistin in the era of new β-lactam/β-lactamase inhibitor combinations. Antibiotics 11:277.

Centers for Disease Control and Prevention (CDC), 2023. Antibiotic resistance threats in the United States, 2023. U.S. Department of Health and Human Services, Atlanta.

Chant C, A Leung and JO Friedrich, 2013. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Critical Care 17:279.

European Centre for Disease Prevention and Control (ECDC), 2023. Antimicrobial resistance surveillance in Europe 2023. ECDC, Stockholm.

Gupta N, A Sharma, R Mehta et al., 2024. Combined ceftazidime–avibactam and aztreonam therapy for metallo-β-lactamase-producing Enterobacterales bloodstream infections. Expert Review of Anti-Infective Therapy 22:203-09.

Han D, Y Zhou, L Wang et al., 2024. Nanopore targeted sequencing for rapid identification of bloodstream infections and antimicrobial resistance genes. Journal of Infection 88:106166.

Hinson C, C Kilpatrick, K Rasa et al., 2024. Global surgery is stronger when infection prevention and control is incorporated: a commentary and review of the surgical infection landscape. BMC Surgery 24:397.

Kaye KS, R Bonomo, J Patel et al., 2023. Sulbactam–durlobactam for treatment of carbapenem-resistant Acinetobacter baumannii infections. Lancet Infectious Diseases 23:1102-13.

Keam SJ, 2024. Cefepime/enmetazobactam: first approval. Drugs 84:737-44.

Konkova LS, EV Rogacheva and LA Kraeva, (2025). New approaches for combating polyresistant ESKAPE pathogens. Russian Journal of Infection and Immunit 15:235-46.

Liu HY, X Zhang, J Wang et al., 2024. Mechanisms of biofilm-associated antimicrobial resistance. Nature Reviews Bioengineering 2:1–14.

Magiorakos AP, A Srinivasan, RB Carey et al., 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for standard definitions. Clinical Microbiology and Infection 18:268–81.

McLeod SM, J Wright, R Bonomo et al., 2024. Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination active against carbapenem-resistant Acinetobacter baumannii. Future Microbiology 19:151-60.

Murray CJL, K Ikuta, F Sharara et al., 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629-55.

O’Neill J, 2016. Tackling drug-resistant infections globally: final report and recommendations. UK Government, London.

Schooley RT, J Biswas, JJ Gill et al., 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat multidrug-resistant Acinetobacter baumannii infection. Antimicrobial Agents and Chemotherapy 61:00954-17.

Smith BL, J Taylor, M Roberts et al., 2024. Structural and functional insights into the AcrAB-TolC efflux system in multidrug-resistant Escherichia coli. Scientific Reports 14:52536.

Tao S, Chen H, Li N, Wang T, Liang W, 2022. The spread of antibiotic resistance genes in vivo model. Canadian Journal of Infectious Diseases and Medical Microbiology 2022:3348695.

Ventola CL, 2024. The antibiotic resistance crisis part 2: management strategies and stewardship solutions. 49:84-92.

Wachino JI, 2025. Horizontal gene transfer systems for spread of antibiotic resistance in Gram-negative bacteria. Microbiology and Immunology 69:367-76.

Wan F, X Liu, M Chen et al., 2024. Molecular de-extinction for discovering ancient antimicrobial peptides. Nature Biomedical Engineering 8:612-24.

Wang Y and Y Yu, 2025. Phage therapy as a revitalized weapon for treating clinical diseases. Microbiome Research Reports 4:35.

World Health Organization, 2023. Global antimicrobial resistance and use surveillance system (GLASS) report 2023. WHO, Geneva.

World Health Organization, 2024. Global action plan on antimicrobial resistance: progress report 2024. WHO, Geneva.

World Health Organization, FAO, WOAH, UNEP, 2024. Political declaration of the United Nations General Assembly High-Level Meeting on antimicrobial resistance. United Nations, New York.